# Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-alectinib-for-patients-with-untreated-alk-positive-non/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Haijing Guan,Yanan Sheng,Wanjie Guo,Sheng Han,Luwen Shi |
| Citations | 21 |
| DOI | 10.1007/s12325-019-00908-7 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2924630395 |
| PMID | 30900201 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Sheng Han](https://scholariq.org/researchers/sheng-han/)

## Paper journal

- [Advances in Therapy](https://scholariq.org/journals/advances-in-therapy/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.